Scynexis SCYX
NASDAQ SCYX
$4.91 -0.24 (-4.66%)
At close: Sep 9, 2026 · 4:00 PM EDT

Scynexis (SCYX) Net Equity Issued and Repurchased (2016 - 2025)

Scynexis' (SCYX) quarterly Net Equity Issued and Repurchased came in at $1000.0 in Q4 2025, up 125.0% quarter-over-quarter from -$4000.0 in Q3 2023.

Analysis

Scynexis (SCYX) Net Equity Issued and Repurchased (2016 - 2025) Analysis & Trends

Scynexis (SCYX) has reported Net Equity Issued and Repurchased for 9 consecutive years, with $1000.0 the latest figure, recorded in Q4 2025.

  • For the quarter ending Q4 2025, Net Equity Issued and Repurchased changed N/A year-over-year to $1000.0; the trailing twelve-month figure through Dec 2025 stood at -$3000.0 (changed N/A YoY), and the FY2025 full-year result was $5000.0, changed N/A from the prior year.
  • Net Equity Issued and Repurchased climbed to $1000.0 in Q4 2025 per SCYX's latest filing, from -$4000.0 in the prior quarter.
  • Across five years, Net Equity Issued and Repurchased topped out at $30.5 million in Q4 2021 and bottomed at -$4000.0 in Q3 2023.
  • Historically, Net Equity Issued and Repurchased has averaged $4.5 million across 4 years, with a median of $450000.0 in 2021.
  • The sharpest annual moves came in 2021 and 2023: Net Equity Issued and Repurchased surged 333.33% in 2021, then plunged 104.0% in 2023.
  • Over 4 years, Net Equity Issued and Repurchased stood at $30.5 million in 2021, then tumbled by 99.67% to $100000.0 in 2022, then slumped by 104.0% to -$4000.0 in 2023, then surged by 125.0% to $1000.0 in 2025.
  • According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered $1000.0, -$4000.0, and $4000.0 for Q4 2025, Q3 2023, and Q2 2023 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Equity Issued and Repurchased (Qtr)
1 Amgen 211.73 Bn 197.74 Bn 7.24 Bn -
2 Gilead Sciences 180.92 Bn 177.74 Bn 6.22 Bn 9.00 Mn
3 Vertex Pharmaceuticals 132.16 Bn 124.30 Bn 2.84 Bn -
4 Regeneron Pharmaceuticals 82.89 Bn 74.90 Bn 3.93 Bn 49.20 Mn
5 Argenx Se 61.41 Bn 56.23 Bn 1.37 Bn -
6 Moderna 53.99 Bn 48.85 Bn 52.00 Mn -
7 Alnylam Pharmaceuticals 34.48 Bn 31.18 Bn 992.69 Mn -
8 Biogen 31.15 Bn 29.86 Bn 1.96 Bn -
9 Roivant Sciences 30.05 Bn 30.05 Bn 1.16 Mn -
10 Scynexis 58.41 Mn -56.29 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 1,000.00
Sep 30, 2023 -4,000.00
Jun 30, 2023 4,000.00
Sep 30, 2022 100,000.00
Mar 31, 2022 2.16 Mn
Dec 31, 2021 30.53 Mn
Sep 30, 2021 2.60 Mn
Jun 30, 2021 800,000.00
Dec 31, 2020 85.85 Mn
Sep 30, 2020 600,000.00
Jun 30, 2020 2.54 Mn
Mar 31, 2020 214,000.00
Dec 31, 2019 36.27 Mn
Sep 30, 2019 3.31 Mn
Jun 30, 2019 4.17 Mn
Mar 31, 2019 2.59 Mn
Dec 31, 2018 958,000.00
Sep 30, 2018 507,000.00
Mar 31, 2018 30.19 Mn
Dec 31, 2017 1.36 Mn